US Stock Market Move | Omvoh's Phase III trial in pediatric ulcerative colitis succeeds; Eli Lilly (LLY.US) rises over 5%, with its stock price hitting an all-time high.

On Tuesday, Eli Lilly (LLY.US) rose over 5% to $1,309.39, hitting an all-time high. On the news front, on October 19, Eli Lilly announced that the Phase III SHINE-2 study of Omvoh in pediatric ulcerative colitis met its primary endpoint; among 52 patients aged 6 to 17 who had a clinical response to Omvoh, 50% achieved clinical remission at week 52. Omvoh is currently approved in the United States for the treatment of adult patients with active ulcerative colitis and Crohn's disease. The company plans to submit the study results to global regulatory authorities to seek expansion of the drug's indications.